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W e  describe the purification and first biochemical 
characterization of an enzymatic activity in v e n o m  from 
the marine snail Conus magus. This enzyme, n a m e d  
conodipine-M, is a novel phospholipase A% with a molec­
ular mass of 13.6 k D a  and is comprised of two polypep­
tide chains linked by one or more disulfide bonds. The 
amino acid sequence of conodipine-M shows little if any 
homology to other previously sequenced phospholipase 
Ag enzymes (PLA^s). Conodipine-M thus represents a 
n e w  group of PLAaS. This is remarkable, since conodi­
pine-M displays a n u m b e r  of properties that are similar 
to those of previously characterized 14-kDa P I ^ s .  The 
enzyme shows little, if any, phospholipase A,, diacylg- 
lycerol lipase, triacylglycerol lipase, or lysophospho- 
lipase activities. Conodipine-M hydrolyzes the sn-2 ester 
of various preparations of phospholipid only in the pres­
ence of calcium and with specific activities that are 
comparable to those of well k n o w n  14-kDa snake v e n o m  
and pancreatic PLA^s. The Conus enzyme binds tightly 
to vesicles of the negatively charged phospholipid 1,2- 
dimyristoyl-sn-glycero-3-phosphomethanol and cata­
lyzes the hydrolysis of this substrate in a processive 
fashion. Conodipine-M does not significantly discrimi­
nate against phospholipids with unsaturated versus sat­
urated fatty acids at the sn-2 position or with different 
polar head groups. Linoleoyl amide and a phospholipid 
analog containing an alkylphosphono group at the sn-2 
position are potent inhibitors of conodipine-M. W e  sug­
gest that the functional resemblance of conodipine-M to 
other PLA-jS might be explained by the utilization of 
similar catalytic residues.
C onus are a group of predatory marine snails that prey on 
fish, molluscs, and polychaete worms (1). Venom from cone 
snails are extraordinarily complex and often contain more than 
100 distinct components. Most venom characterizations have 
focused on small disulfide-rich peptides tha t target selectively 
to receptors and ion channels on nerve and muscle cells. Known 
targets include calcium channels (a>-conotoxins) (2-4), sodium 
channels (/a- and S-conotoxins) (5-8), iV-methyl-D-aspartate re­
ceptors (conantokins) (9-11), nicotinic acetylcholine receptors
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(a-conotoxins) (12-17), and vasopressin receptors (cono- 
pressins) (18, 19). Small neuroactive molecules, e.g. serotonin, 
have also been found (20).
Although larger protein components are present in cone ven­
oms, these are generally less well characterized biochemically. 
Reports have included a convulsion-inducing peptide from Co­
nus geographus, with an apparent molecular weight of 13,000 
(21); a cardiotonic glycoprotein (approximate molecular weight 
of 25,000) from C onus stria tu s, which appears to act on voltage- 
sensitive sodium channels (22, 23); a protein from Conus m a ­
g u s  (molecular weight estimated to be between 45,000 and 
65,000), which induces powerful rhythmic contractions of 
guinea pig vas deferens (24); and a 25,000 molecular weight 
protein from Conus d is tans, which inhibits neurotransmitter 
release in ra t hippocampus (25).
In this study, we have characterized a 13.6-kDa component 
from the venom of the fish-eating cone snail, C. m agus. Novel 
to- and a-conotoxins have been isolated from this species pre­
viously (13, 26). We detail the isolation and characterization of 
a polypeptidic venom component that we show to be a novel 
phospholipase A2 (PLA2).1 This is the first biochemical charac­
terization of an enzymatic activity from Conus venoms.
Low molecular mass secreted PLA2s (14—18 kDa) have been 
reported from a wide variety of other venoms (snakes, insects, 
and lizards) as well as mammalian pancreatic and inflamma­
tion fluids (27-30). These enzymes hydrolyze the ester a t the 
sn -2 position of phosphoglycerides. Snake venom and pancre­
atic PLA2s are particularly well characterized (31, 32). All 
require millimolar concentration of calcium as a catalytic co­
factor. In addition to PLAZ activity, some of these venom pro­
teins show potent neurotoxicity (33-35). For instance 0-bunga- 
rotoxin, from the Formosan banded krait (B ungarus  
m ultic inctus) (36) and notexin isolated from the Australian 
tiger snake N otechis scu ta tus scu ta tus  (37) exert potent neuro­
toxic action by inhibiting the release of acetylcholine from 
nerve terminals in neuromuscular junctions (38). (3-Bungaro- 
toxin consists of a PLA2 chain covalently bonded by a disulfide 
bridge to a polypeptide (molecular weight ~ 20,000) (29). The 
PLA2 chain of /3-bungarotoxin is homologous to notexin. En-
1 The abbreviations used are: PLA2, phospholipase A^; DMPM, 1,2- 
dimyristoyl-sn-glycero-3-phosphomethanol; [3H]DPG, l-palmitoyl-2- 
[9,10-[3H]]palmitoyl-sn-glycerol; [3H]DPPA, l-palmitoyl-2-[9,10-[3H]] 
palmitoyl-sre-glycero-3-phosphate; [3H]DPPC, l-palmitoyl-2-[9,10-[3H]] 
palmitoyl-sn-glycero-3-phosphocholine; [3H]DPPE, l-palmitoyl-2-[9,10- 
[3H]]palmitoyl-src-glycero-3-phosphoethanolamine; [14C]PAPC, 1-pal- 
m itoyl-2-[l-14C]arachidonyl-sn-glycero-3-phosphocholine; [14C]SAPI, 1- 
stearoyl-2-[l-14C]arachidonyl-sn-glycero-3-phosphoinositol; [3H]SAPS,
l-stearoyl-2-[5,6,8,9,ll,12,14,15-[3H]]arachidonyl-sn-glycero-3-phos- 






























F ig . 1. HPLC pu rifica tio n  of conodipine-M . Panel A, extracted crude venom (see “Experim ental Procedures”) was applied to a Vydac 
reversed phase C18 column (10-jitm particle size; 22-mm inner diam eter X  25-cm length) and eluted with a  gradient th a t began a t 95% A, 5% B 
for 5 min and increased to 100% B over 28 min. B was held a t 100% for 5 min and then decreased to 5% over 4 min. The flow ra te  was 4 ml/min. 
Fractions were collected every 3 m in beginning a t  12 min. Panel B, m aterial eluting a t 34.3 min (arrow in panel A) was ru n  on a Vydac reversed 
phase C18 column (10-/xm particle size, 10-mm inner diam eter x 25-cm length) and eluted by beginning a t 70% A, 30% B for 4 min; increasing to 
36% B over 6 min; and th en  increasing to 56% B over 60 min. The flow ra te  was 3 ml/min. Fractions were collected every 1.0-1.25 min, beginning 
a t  3 min. Panel C, m aterial eluting a t 23.3 min (arrow in  panel B) was run  on a Microsorb MV reversed phase C18 column (5-jU.m particle size, 
4.6-mm inner diam eter x 25-cm length). The gradient began a t 40% C, 60% buffer D for 1 min; increased to 70% D over 30 min; and increased to 
80% D over 60 min. The flow ra te  was 1 ml/min. Fractions were collected according to visual inspection of the protein absorbance. Panel D, m aterial 
eluting n ear the peak a t 47.4 min (arrow in panel C) was run  again using the  same conditions as in panel C. Buffer A was 0.1% trifluoroacetic acid; 
buffer B was 0.1% trifluoroacetic acid, 90% acetonitrile in panels A  and B. Buffer C was 0.1% trifluoroacetic acid, 2% MeOH, 98% H20 ; buffer D 
was 0.09% trifluoroacetic acid, 90% MeOH, 10% H 20  in panels C and D. I t  should be noted th a t prolonged use of trifluoroacetic acid/methanol in 
th e  Microsorb MV column is not recommended by the m anufacturer because of potential hydrolysis. The absorbance was monitored a t 237 nm in 
panel A  and a t 214 nm in  panels B-D.
zym es isolated from the venoms o f N aja naja a tra  and N aja  
niggricollis, however, show more potent PLA2 activity, have 
less presynaptic effects, and are much less lethal (39). More 
than 50 proteins w ith  PLA2 activity have been isolated from 
snake venom s and show substantial sequence homology with  
each other and with PLA2 enzym es isolated from mammalian  
pancreas and inflamm atory exudates (40, 41). Sequence infor­
m ation reveals that the C. m agus enzyme reported here differs 
substantially from any other PLA2 characterized to date and 
defines a new group of these enzymes.
EXPERIMENTAL PROCEDURES 
Materials
C. magus specimens were collected in the Philippines. Venom was 
removed from dissected ducts, lyophilized, and stored a t -7 0  °C until 
use (42). /3-Mercaptoethanol was from Pierce, dithiothreitol was from 
Boehringer M annheim , trifluoroacetic acid (sequencing grade) was 
from Aldrich, and acetonitrile (UV grade) was from Baxter.
The preparation of l-0-hexadecyl-2-deoxy-2-S-thiohexadecanoyl-sn- 
glycero-3-phosphocholine and DMPM has been described previously 
(43, 44). [3H]DPPC (50 Ci/mmol), [14C]PAPC (50 mCi/mmol), and 
[14C]SAPI (50 mCi/mmol) were from DuPont NEN. [3H]DPPE (10 mCi/ 
mmol), [3H]DPPA (5 mCi/mmol), and [3H]SAPS (400 mCi/mmol) were 
prepared as described (45, 46). [3H]DPG was synthesized by treating  
0.15 mg of [3H]DPPC (50 mCi/mmol) in 0.2 ml of 200 m M  sodium 
phosphate, 400 p.M ZnCl2, 1 m M  2-m ercaptoethanol, pH 7.0, w ith 30 jxg  
of phospholipase C (Bacillus cereus, Sigma P-7147) for 2 h a t 37 °C with 
vigorous shaking. The reaction m ixture was extracted three tim es with 
ether, the extract was dried over anhydrous Na2S 0 4, and the residue 
w as dissolved in e ther and applied to a  silica gel TLC plate. The plate 
was developed with chloroform:ether (9:1), the product band (visualized 
w ith iodine) was scraped from the plate, and the  product was eluted
with ether. The PLA2 inhibitors linoleoyl amide and MG14 were pre­
pared as described (47-49). Porcine pancreatic PLAa was obtained as a 
generous gift from Professor M. K. Ja in  (University of Delaware) (50), 
bee venom PLA2 was from Boehringer M annheim, and pancreatic lipase 
was from Sigma (L-0382).
Protein Purification and  Structural Analysis
Venom Extraction—Crude lyophilized venom (1.99 mg) was dissolved 
in 8 ml of ice-cold buffer containing 50 mM Tris-HCl, pH 7.4 a t room 
tem perature, 120 mM NaCl, 5 mM KC1, 1 mM MgCl2, and 2 mM CaCl2 
and sonicated five tim es for 10 s each a t setting 8 using a  Sonifier 
(model LS-75, Branson Instrum ents). During sonication the vessel was 
cooled with an  ice bath. The m ixture was centrifuged a t 17,200 x g  for 
10 min a t 4 °C. The supernatan t was retained, and an additional 2 ml 
of buffer was added to the  pellet, and the m ixture was sonicated three 
tim es as above. The m ixture was centrifuged as above, and the super- 
n a tan ts were combined and centrifuged again. Supernatants were 
placed in an  empty polypropylene spin column w ith a  cut-to-size GF/C 
filter (W hatman) placed on the column support. The column was then 
centrifuged a t 200 X  j  a t 4 °C, and 25% of the  filtrate was used for 
fu rther purification by HPLC. The rem aining filtrate was stored a t 
-7 0  °C.
HPLC Purification—HPLC was carried out w ith HPXL pumps and a 
Dynamax model UV1 detector (Rainin Instrum ents, Woburn, MA). 
Vydac and Microsorb MV columns were from Rainin. See Fig. 1 for 
column specifications and buffer conditions. The concentrations of pu­
rified conodipine-M were determined from the OD280 using an extinc­
tion coefficient of 10/cm/percent (OD = 1 is 1 mg/ml). This num ber was 
derived from yields of protein obtained during amino acid sequencing of 
conodipine-M.
Protein Reduction and Alkylation—In Experim ent 1, disulfide bonds 
were reduced by adding 50 /laI of conodipine-M (200 pmol dissolved in 
HPLC elution buffer, Fig. ID) to 200 ju.1 of reducing buffer 1. Reducing 
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E lu tion  tim e  (m in)
Fig. 2. C o n od ip ine-M  h a s  tw o  su b u n its . Native and modified conodipine-M were analyzed by HPLC. HPLC conditions are the same for each 
panel and are described in Experim ent 1 under “Experim ental Procedures.” Panel A, unmodified conodipine-M, when chromatographed as 
described below, elutes a t  27.4 min. Electrospray m ass spectrom etry of th is m aterial shows a molecular m ass of 13,602. Panel B, reduction of 
conodipine-M (described under “Experim ental Procedures”) produces two prim ary protein absorbances with m igration tim es (24.7 and 31.9 min) 
which differ from unmodified m aterial. Mass spectroscopy of these proteins shows molecular m asses of 8,571 and 5,036. The arrow indicates the 
expected m igration tim e of unmodified conodipine-M. The sum of the m olecular m asses of these two proteins approxim ates th a t of the intact 
protein. Panel C, reduction and alkylation of conodipine-M (described in under “Experim ental Procedures”) also results in two protein absorbances 










threitol, and 1 mM EDTA adjusted to pH 7.3 with H:)P 0 4 and bubbled 
with nitrogen. The reaction vessel was flushed w ith nitrogen and incu­
bated  a t 65 °C for 15 min. The reduced protein was analyzed by HPLC. 
A portion of the  reduced protein subunits (see Fig. 2B) was subm itted 
for m ass spectrometry analysis. The rem ainder was alkylated by adding 
T ris base directly to the  HPLC fractions to raise the  pH to between 7 
and 8 (m easured by pH paper) and adding 4 fi1 of 4-vinylpyridine. The 
solution was reacted a t room tem perature in the  dark  for 25 min, and 
alkylated peptides were purified by HPLC. In  Experim ent 2, conodi­
pine-M was reduced, alkylated, and th en  purified by HPLC (Fig. 2C). 
For th is experiment, conodipine-M (3.2 nmol in  800 ju.1 of HPLC elution 
buffer; Fig. ID) was added to 80 jj.1 of reducing buffer 2. Reducing buffer
2 was 0.25 M N a2H P 0 4, 100 mM fi-mercaptoethanol, 10 mM dithiothrei­
tol, and 10 mM EDTA (pH not adjusted; solution was bubbled with 
nitrogen). The pH of the combined conodipine-M and reducing buffer 2 
solution was between 7 and 8 as m easured by pH  paper. The reaction 
vessel was flushed w ith nitrogen and incubated a t  65 °C for 15 min and 
th en  allowed to cool to room tem perature. Six jxl of 4-vinylpyridine was 
then  added and the  solution reacted a t room tem perature for 25 m in in 
the  dark. The reaction mix was th en  diluted to 2.4 ml using 0.1% 
trifluoroacetic acid (to lower the pH) and analyzed by HPLC. For all 
HPLC protein reduction and alkylation reactions, a  Vydac (218TP54) 
C18 reversed phase column was used (5-|xm particle size, 4.6-mm inner 
diam eter X 25-cm length). The solvent gradient used was 20% B until 
the base-line absorbance decreased to w ithin 10% of its original value 
and then  to 100% B over 40 min. Buffer A was 0.1% trifluoroacetic acid; 
buffer B was 0.1% trifluoroacetic acid, 60% acetonitrile. The flow rate 
was 1 ml/min, and detection was a t 220 nm.
Enzymatic Digests
Pyroglutamate Aminopeptidase—The pyroglutam ate a t the  NH2 te r­
m inus was removed by adding purified a-chain of conodipine-M (66 ju.1 
in HPLC elution buffer, CH3CN blown off with N 2; see Fig. 2) to 284 |xl 
of buffer (50 mM Na2H P 0 4, 10 mM (3-mercaptoethanol, 1 mM dithio­
threitol, and 1 mM EDTA adjusted to pH 7.3 w ith H 3P 0 4) containing 0.4 
mg (16 of protein) of freshly dissolved pyroglutam ate aminopepti­
dase preparation (Boehringer Mannheim). The reaction mix was incu­
bated for 1 h  a t 37 °C. The cleaved protein was purified using a reversed 
phase C18 Microsorb MV column (Rainin Instrum ents, 86-203-C5). 
E lution buffer A was 0.1% trifluoroacetic acid; buffer B was 0.1% 
trifluoroacetic acid, 60% acetonitrile. A linear gradient of 20-100%  B 
over 80 m in was used to elute the peptide. The flow ra te  was 1 ml/min.
Endoproteinase Lys-C—a-Chain of conodipine-M was initially dis­
solved in  5 jxl of CHjCN followed by 40 (xl of 0.1 M N aH C 03, pH 8.5. To 
th is was added 1.0 jxl containing 0.1 jxg of endoproteinase Lys-C (Boeh­
ringer Mannheim, 1047825) in 50 mM Tricine, pH  8.0, 10 mM EDTA. 
The reaction mix was incubated overnight a t 37 °C. Digestion frag­
m ents were purified using a  reversed phase C18 column (Vydac 
218TP52). Elution buffer A was 0.1% trifluoroacetic acid; buffer B was
0.1% trifluoroacetic acid, 80% acetonitrile. A linear gradient of 5—95% B
over 90 min was used to elute the peptides. The flow ra te  was 0.15 
ml/min.
Endoproteinase Arg-C—a-Chain of conodipine-M was initially dis­
solved in  5 (il of CH3CN. Endoproteinase Arg-C (Boehringer M annheim 
1370529), 0.5 p.g in 95 jxl of buffer (90 mM Tris-HCl, 8.5 mM CaCl2, 5 mM 
dithiothreitol, 0.5 mM EDTA, pH 7.6), was added, and the reaction 
m ixture was incubated for 18 h  a t 37 °C. Digestion fragm ents were 
purified as described above for endoproteinase Lys-C.
Sequence Analysis—Amino acid sequencing was performed with 
Edm an chemistry on an Applied Biosystems 477A Protein Sequencer a t 
the  Protein/DNA Core Facility a t the  University of U tah  Cancer Center.
Mass Spectrometry—Molecular m asses of conodipine-M and its sub­
units were determined using a triple quadrupole m ass spectrom eter 
TSQ 700 (Finigan-M at, San Jose, CA) equipped with an  electrospray 
source.
Membrane Binding
Membrane Preparation—Neocortices were bluntly  dissected from 
eight Sprague-Dawley ra ts  (200-220 g, male) and placed in 150 ml of 
ice-cold 50 mM H EPES buffer, pH 7.4 using NaOH. The tissue was 
homogenized with a  B rinkm ann Polytron for 30 s using a PTA 20S 
probe. The homogenate was fu rther diluted to 200 ml and centrifuged a t 
1,000 x g  for 10 m in a t 4 °C. The supernatan t was removed and 
centrifuged a t 48,000 x g  for 10 min. The supernatan t was discarded, 
and the pellet was resuspended in a  total of 200 ml of buffer and 
centrifuged a t 48,000 x g  for 10 min. The supernatan t was discarded, 
the pellet was weighed, and 1 ml of buffer/125 mg of pellet was added. 
The tissue was suspended using a Potter glass-Teflon homogenizer 
using eight strokes a t 800 rpm. Membranes were frozen in liquid 
nitrogen a t —70 C un til use.
PHJIsradipine Binding—Neocortical m em branes (50 fig as m easured 
using the Bio-Rad microprotein assay) were incubated a t 37 °C for 60 
m in in  2 ml of 50 mM Tris-HCl, pH 7.4, 1 mM CaCl2, 1 mg/ml lysozyme 
(Sigma L-6876), w ith 100 pM [3H]isradipine ((+ )-[met/ryZ-3H]PN 200­
110, 7 0 -8 5  Ci/mmol, Amersham) in the  presence or absence of venom 
fractions (typically 1/10,000 of the fraction during preparative phases of 
the purification, see Fig. 1). Venom fractions were routinely dried using 
a  Speed Vac (Savant) in  the presence of 50 fig of lysozyme to decrease 
nonspecific adsorption to the  tubes. Nonspecific binding of [3H]isradi- 
pine was determ ined using 100 nM isradipine. The reaction was stopped 
by filtering the  sam ples through GF/C filters, followed by two 4-ml 
washes with ice-cold buffer. Samples were then  analyzed using a scin­
tillation counter. Fractions th a t showed 95—100% inhibition were sub­
sequently tested  a t lower concentrations to determ ine the relative 
am ount of activity p resent in all of the fractions. For later experiments 
w ith purified conodipine-M, the  reaction volume was decreased to 500 
lil, [3H]isradipine was increased to 200 pM, m em brane protein was 
increased to 500 fig, lysozyme was reduced to 0.1 mg/ml, and nonspe­
cific binding was defined w ith 10 |xM nifedipine (Sigma) (prepared 

























for 24 s using a Classic cell harvester from Skatron Instrum ents (Ster­
ling, VA) using Skatron 11734 filterm ats. The la tte r  protocol reduced 
the  am ount of venom m aterial needed and allowed 12 samples to be 
filtered simultaneously.
Lipolytic Assays
For all lipolytic assays, stock solutions of conodipine-M were in w ater 
containing 1 mg/ml lysozyme (added during lyophilization). Spectropho- 
tometric assays to detect PLA2 activity were carried out with 1-0- 
hexadecyl-2-deoxy-2-S-thiohexadecanoyl-sn-glycero-3-phosphocholine 
as described previously (44). The reaction m ixture contains 0.5 mM 
thiolester, 4 mM Triton X-100, 0.1 M KCI, 10 mM CaCl2, 0.8 mM 5,5'- 
dithiobis(2-nitrobenzoic acid) (Aldrich), and 25 mM Tris, pH 8.0. The 
reaction m ixture (0.35 ml) was placed in a  therm osta tted  cuvette 
(25 °C), 0.1 fjLg of conodipine-M was added, and the  absorbance a t  412 
nm  was monitored.
Hydrolysis of small unilam ellar DMPM vesicles was carried out 
using a  pH -stat as described previously (43), and 4-ml reaction m ixtures 
contained 0.6 mM CaCl2, 1 mM NaCl, 0.6 mg of DMPM, and typically 0.3 
fig of conodipine-M. For the  analysis of inhibitors, assays were carried 
out under conditions th a t  m easure the initial velocity (51), and 4-ml 
reaction m ixtures contained 2.5 mM CaCl2, 1 mM NaCl, 20 /xg of poly­
myxin B sulfate (Sigma), 0.6 mg of DMPM, and typically 0.1 /xg of 
conodipine-M.
In  some cases, radiom etric assays of PLA2 activity were carried out. 
Covesicles of nonlabeled DMPM vesicles containing radiolabeled phos­
pholipids were prepared as described previously (45). The reaction 
m ixtures were extracted with organic solvent, and the am ounts of 
liberated radioactive fa tty  acids were analyzed as described previously 
(45). In  th is way the calcium dependence of PLA2 activity of conodi­
pine-M was m easured using reaction m ixtures with 0.3 mg of DMPM 
vesicles containing 120,000 cpm of [3H]DPPC in 2 ml of 10 mM HEPES, 
100 mM NaCl, 100 mM EGTA, pH 7.4. The m ixtures also contained 
different am ounts of 1 M K,2CaEGTA solution to give the desired con­
centrations of free calcium (52). Reactions were in itiated  by the addition 
of 0.04 jxg of conodipine-M and were quenched with organic solvent 
a fter a 10-min incubation a t 20 °C. Reactions for determ ining the pH 
dependence of conodipine-M-catalyzed vesicle hydrolysis were carried 
out as above except th a t the buffer was 10 mM HEPES, 100 mM NaCl,
1 mM CaCl2, pH 6-9 .
Competitive substrate  specificity studies using the double radioiso­
tope method were carried out as described (45). The reaction m ixtures 
contained 0.6 mg of sonicated DMPM vesicles w ith 1 x 106- 8  x 106 cpm 
of 3H- and 14C-labeled phospholipids in 4 ml of 0.6 mM CaCl2, 1 mM 
NaCl, 20 jxg of polymyxin B a t 21 °C. Reactions were carried out in the 
pH -stat w ith 0.07 ;u,g of conodipine-M (added last) and were quenched 
w ith organic solvent after 120-130 nmol of titra n t was consumed. 
Reactions with DMPM vesicles containing [14C]PAPC and [3H]DPG 
were quenched and extracted with organic solvent as described above. 
The residue from the extract was dissolved in low boiling petroleum 
ether:ether:acetic acid (70:30:1), and nonlabeled arachidonic acid and
1,2-dioleoyl-sn-glycerol (Sigma) were added as m arkers. The mixture 
w as applied to a  silica gel TLC plate (4 x 12 cm), and the plate was 
developed with the sam e solvent. Regions corresponding to fatty acid 
and diacylglycerol were scraped from the plate, and the  silica was 
soaked in scintillation fluid for 1 h  followed by scintillation counting. 
Relative kQBJK m values for the radioactive substra tes were calculated 
using Equation 4 of (45).
Studies to m easure the  positional specificity of the phospholipase 
activity of conodipine-M were carried out with reaction m ixtures of 200 
/xg of l-palmitoyl-2-oleoyl-sre-glycero-3-phosphomethanol in 4 ml of 2.5 
mM CaCl2, 1 mM NaCl, pH 8.0, containing 20 fig of polymyxin B a t 21 °C 
in  the pH-stat. After about 30% of the substrate  was hydrolyzed (30 /j.1 
of 3 mM NaOH titran t), the  reaction was quenched by the addition of 4 
ml of 0.1 m EDTA, 2 m NaCl, pH 7.0, followed by 0.56 ml of 88% formic 
acid and 4 ml of ethyl acetate. After mixing on a  vortex mixer, the layers 
were separated by centrifugation, and the  organic layer was transferred 
to a  new tube. The aqueous phase was extracted w ith a second portion 
of ethyl acetate, the  extracts were combined, and the solvent was 
removed with a  stream  of nitrogen. To the residue were added 0.5 ml of 
e th e r and 50 ftl of m ethanol, and sufficient diazom ethane in e ther was 
added until the  yellow color persisted. After 30 m in a t room tem pera­
tu re, the solvent was removed with a stream  of nitrogen. The residue 
was taken  up in ether, and a portion was analyzed by gas chromatog­
raphy on a  DB-5 column (J  & W Scientific). Peaks corresponding to 
m ethyl oleate and m ethyl palm itate were integrated, and the peak 
areas obtained from a control reaction (omission of conodipine-M) were 
subtracted from those obtained in the presence of enzyme.
RESULTS
P urification  o f  C onodipine-M —Conodipine-M was originally 
identified in a general screen of Conus venoms for new calcium 
channel blockers. A number of crude cone venoms were exam­
ined for their ability to inhibit the binding of [3H]isradipine (a 
ligand specific for L-type calcium channels) (53, 54) to rat 
neocortical membranes. Several Conus venoms were found to 
inhibit [3H]isradipine binding. The inhibition of this binding by 
C. m agus venom was found to be exceptionally potent (55) and 
was therefore targeted for purification.
Crude venom from C. m agus  was extracted and initially 
chromatographed using a preparative HPLC column (see Fig. 
1A). Fifteen fractions were collected and tested, and fraction 8 
eluting at 34.3 min was found to inhibit [3H]isradipine binding 
to ra t brain membranes. This fraction was rechromatographed 
using a semipreparative column and a shallower gradient. The 
eluant resolved into two major broad peaks, as well as a num­
ber of minor components (see Fig. IB). Activity (as measured by 
the isradipine binding assay) was associated with the earlier 
eluting major peak in Fig. IB.
Further purification was carried out using an analytical 
HPLC column (4.6-mm inner diameter X 25-cm length). Reso­
lution was difficult because of the presence of a t least three 
closely migrating components (Fig. 1C). The trifluoroacetic ac- 
id/acetonitrile buffer system used in the initial steps of purifi­
cation did not fully resolve these components (data not shown). 
The best resolution was obtained with a very slow gradient of 
trifluoroacetic acid/methanol buffer (see Fig. 1C for buffer con­
ditions) using a reversed phase C18 Microsorb MV column. 
Using these conditions, a center cut of the middle peak reliably 
gave a homogeneous appearing peak on rechromatography (see 
Fig. ID). Although the material in Fig. 1C did not appear 
chromatographically homogeneous, the amount of [3H]isradi- 
pine binding activity was proportional to the protein absorbance 
across all peaks, suggesting that the active material might be 
present as multiple isoforms. The major component was purified 
(see Fig. ID) and was the material that was further characterized 
below, which we have called conodipine-M.
B iochem ical C haracterization o f  C onodipine-M —Prelimi­
nary analysis of conodipine-M suggested tha t the purified ma­
terial was not a typical Conus peptide of 10-30 amino acids in 
length. Chromatography on reversed phase HPLC columns 
gave a late eluting, broad peak, much more characteristic of 
larger polypeptides than of small peptidic conotoxins charac­
terized previously. When characterized by mass spectrometry, 
conodipine-M was found to have a molecular mass of 13,602, 
indicating a large polypeptide. Conodipine-M was reduced and 
rechromatographed on HPLC. Two protein peaks were detected 
and when analyzed by mass spectrometry, gave values of M r = 
8,571 and 5,036 (see Fig. 2). These results suggest two polypep­
tide chains, joined together by interchain disulfide bonding. As 
detailed below, amino acid sequence analysis of reduced and 
alkylated conodipine-M verified the presence of two polypep­
tide chains.
Initial attempts at amino acid sequencing revealed that the 
NH2 terminus of the a-chain is blocked. The a-chain was re­
duced, alkylated (pyridylethylated), and purified by reversed 
phase HPLC. The alkylated a-chain was unblocked by diges­
tion with pyroglutamate aminopeptidase, repurified, and se­
quenced successfully through the first 34 residues. To analyze 
the remainder of the chain, digests with endoproteinase Lys-C 
(cleaves peptide bonds at the COOH-terminal side of Lys resi­
dues) and endoproteinase Arg-C (cleaves peptide bonds COOH- 
terminally at Arg residues) were performed. Fragments were 
isolated by reversed phase HPLC and sequenced. The /3-chain 
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T a b l e  I
Sequence analysis of conodipine-M
The sequences of the a- and /3-chains of conodipine-M are shown. Enzym atic cleavage products are indicated. The 0-chain of conodipine-M is 
compared w ith the  /3-chain of /3-bungarotoxin (29). The first 34 amino acids of the a-chain of conodipine-M were analyzed after digestion with 
Pyroglutamate aminopeptidase to unblock the NH2 terminus. Endoproteinase Lys-C and Arg-C digestion fragm ents were analyzed to determine 
the rem ainder of the a-chain sequence. X  = uncertain amino acid. Underlined residue = enzymatic cleavage site.
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T a b l e  II 
PLA2 sequence comparisons
Sequences for porcine pancreas PLA2 (28, 29), the  a-chain of the two-subunit /3-bungarotoxin (29), the viper Bitis gabonica PLA2 (27), the cloned 
sequence for bee venom PLAj (30), and the a-chain of conodipine-M are compared (see also Table IV). Note th a t conodipine-M lacks the 
Tyr/Trp-Cys-Gly-Xaa-Gly (underlined) found in all other secreted PLA^s. This sequence is postulated to be a calcium binding loop critical to 
catalytic activity. Also note the significantly sm aller size of conodipine-M. The table was modified from Kondo et al. (29). S tandard  one-letter amino 






































Results of the sequence analysis are summarized in Table I. It 
is noteworthy that the sequence of the a-chain of conodipine-M 
is considerably shorter than the a-chain of other two-subunit 
PLA2s (e.g. compare /3-bungarotoxin in Table II). Mass spec­
trometry measurements of conodipine-M, however, confirmed 
the size of the indicated sequences of the a- and /3-chains (see 
below).
In the conodipine-M sequences, a few residues could not 
positively be assigned (indicated by X in  the tables). In several 
cases, these residues appear as blanks in the sequencing run. 
These blanks appeared in multiple sequencer runs, always in 
the same position. Peptides from Conus contain a number of 
unusual amino acids and post-translational modifications 
which appear as blanks during sequencing (9). It is likely that 
the unassigned residues in the middle portions of the sequence 
represent such modifications (1 or 2 residues at the COOH 
terminus could not be assigned with certainty because of a 
diminishing signal). The size of any post-translational modifi­
cation is small, however. By comparing the observed mass 
(measured by mass spectrometry) with the calculated mass of 
the sequence shown in Table I, the average mass for the unas­
signed residues in the a-chain is 132.2 ((8,571 -  7,910)/5) and 
in the /3-chain 137.0 ((5,036 -  4,625)/3).
Although conodipine-M potently inhibits the binding of isra- 
dipine to L-type calcium channels, several lines of evidence 
suggest that this might not be the result of direct competition. 
As shown in Fig. 3 the inhibition of isradipine binding depends 
on the time of preincubation of conodipine-M with cortical 
membranes. These results raise the possibility that the inhibi­
tion may be indirect.
The larger size of conodipine-M and the time course of isra­
dipine binding led us to investigate whether conodipine-M had 
any enzymatic activity. Since many venoms have been reported 
to contain PLA2s, we tested conodipine-M for its ability to 
hydrolyze phospholipids. As shown in the following section, 
conodipine-M is indeed a PLA2.
The sequence of conodipine-M can be compared to other 
known PLA2s. The sequence of the a-chain of conodipine-M and 
group I—III PLA2s is shown in Table II. Although conodipine-M 
shows little homology to any known PLA2, certain catalytic 
residues may be similar (see Tables II, IV and “Discussion”).
C onodipine-M  H as P LA 2 A ctiv ity—Initial studies of the 
PLA2 activity of conodipine-M were carried out with a spectro- 
photometric assay using the sn -2 thiolester phospholipid ana­
log l-0-hexadecyl-2-deoxy-2-S-thiohexadecanoyl-sre-glycero-3- 


























Fig. 3. Tim e dependence  of conodipine-M  inh ib itio n  of [3H]is- 
rad ip in e  b inding. Cortical ra t bra in  m em brane was incubated in  the 
presence or absence of 2 nM  conodipine-M a t 37 °C for the indicated 
lengths of time. Specific binding was defined as the  difference between 
[3H]isradipine counts bound in the absence (total binding) and presence 
(nonspecific binding) of 10 jim nifedipine (see “Experim ental Proce­
dures”). D ata were acquired in duplicate and the  results averaged.
of the sn-2  thiolester generates an SH group that is detected 
with Ellman’s reagent. Using the conditions given under 
“Experimental Procedures,” conodipine-M displays significant 
PLA2 activity; the specific activity was 22 mmol/min/mg for 
conodipine-M versus 4 mmol/min/mg for bee venom PLA2 meas­
ured under identical conditions.
Vesicles of the anionic phospholipid DMPM have been used 
extensively to detect and characterize the kinetics of hydrolysis 
of the sn-2  ester of phospholipids by PLA2s (43, 56, 57), and a 
brief overview of this system is given here as it relates to the 
action of conodipine-M on DMPM vesicles. Secreted PLA2s 
(molecular masses of 14 kDa) bind irreversibly to DMPM ves­
icles and hydrolyze all of the substrate in the outer layer in a 
processive fashion termed scooting mode hydrolysis (enzyme 
does not leave the surface). The reaction progress stops when 
all of the outer layer substrate in enzyme-containing vesicles 
has been hydrolyzed. At this point the reaction products re­
main in enzyme-containing vesicles, and the vesicles remain 
structurally intact. As shown in Fig. 4, the reaction ceases after 
a limited amount of total DMPM is hydrolyzed by porcine 
pancreatic PLA2. This is because the inner layer DMPM is not 
hydrolyzed, and there are more vesicles than enzyme, and the 
enzyme does not hop from one vesicle to another. Thus, the 
total mol of product formed is equal to the mol of catalytically 
active enzyme times the mol of substrate in the outer layer of a 
DMPM vesicle (58).
As shown in Fig. 4, the addition of conodipine-M to DMPM 
vesicles leads to the immediate onset of lipolysis. With cono- 
dipine-M, the hydrolysis of DMPM vesicles does not stop 
abruptly, but a steady-state velocity is seen later in the reac­
tion progress (Fig. 4). This continued reaction could be caused 
either by slow dissociation of conodipine-M from vesicles fol­
lowed by rebinding to different vesicles (slow hopping) and/or 
by conodi pine-M-promoted fusion of vesicles; such fusion would 
bring substrate into substrate-depleted, enzyme-containing 
vesicles. In any case, the fact that both conodipine-M- and 
porcine pancreatic-catalyzed reactions produce similar 
amounts of products before the reaction ceases (or slows) indi­
cates that a large fraction, perhaps all, of the conodipine-M 
mass has lipolytic activity, and thus this activity is not due to 
a minor contaminant.
The addition of the cationic peptide polymyxin B leads to 
rapid intervesicle exchange of DMPM, and this replenishes the
Time (min)
Fig. 4. R eaction  p rog ress curves fo r th e  hydrolysis of sm all 
u n ilam ella r vesicles by  0.3 fig o f po rcine p an crea tic  PLA,2 (solid  
lin e ) an d  0.3 fig o f conodipine-M  (dashed  line). O ther conditions 
are given under “Experim ental Procedures.”
substrate in enzyme-containing vesicles. As a result, the initial 
reaction velocity (when the mol fraction of substrate in the 
vesicle is close to 1) is prolonged, and the progress curves are 
linear for several min (51). Under such conditions conodi- 
pine-M displays a specific activity of 200 s” 1, which is similar 
to that of porcine pancreatic PLA2 (320 s -1) (59). Further 
support that conodipine-M has lipolytic activity comes from an 
additional experiment. Conodipine-M was chromatographed on 
an HPLC column. The lipolytic activity of each fraction was 
measured using the DMPM/polymyxin B assay, and as shown 
in Fig. 5, the profile of lipolytic activity exactly matches the 
peak of protein eluting from the column. Further indication of 
the purity of conodipine-M is evident from HPLC analysis of 
reduced and alkylated material. As shown in Fig. 2C, when 
alkylated conodipine-M (43.5 ju-g) is chromatographed, two 
sharp protein absorbances are seen (A and B chains). Contam­
inant peaks (if any) represent no more than 0.1% of the total 
protein absorbance a t 220 nM.
Vesicles of l-palmitoyl-2-oleoyl-src-glycero-3-phosphometha- 
nol were used to test the positional specificity of the esterase 
activity of conodipine-M. Such vesicles were readily hydro­
lyzed, and gas chromatographic analysis of the extracted fatty 
acid fraction shows tha t the major product is oleic acid (<5% of 
the fatty acids formed is palmitic acid). Thus, conodipine-M has 
little, if any, PLA, activity.
C onodipine-M  Is  a  C alcium -dependent P L A 2—When CaCl2 
in the reaction buffer was replaced by 1 mM EDTA, no hydrol­
ysis of DMPM vesicles by conodipine-M was detected. The 
activity measured in the presence of 0.1 mM or 2.5 mM CaCl2 is 
the same within experimental error. To measure the depend­
ence of the reaction velocity on concentrations of calcium below 
0.1 mM, a radiometric PLA2 assay was utilized with buffered 
calcium and pH to establish the precise concentration of free 
calcium (see “Experimental Procedures”). In these studies the 
hydrolysis of [SH]DPPC present in DMPM vesicles is meas­
ured. The results in Fig. 6 show that the reaction velocity 
increases over the range 0 -8 0  pM calcium and gradually de­
creases as the calcium concentration approaches 300 fj,m. The 
pH-rate profile of the PLA2 activity of conodipine-M was meas­
ured under the same conditions, and the rate increased as the 
pH was increased from 6.0 to 7.5 and then remained constant 
up to pH 9.0 (not shown).
Substra te  Specificity  o f  Conodipine-M —Substrate prefer­
ences of conodipine-M for different phospholipids were ana­
lyzed using the double radioisotope method (45). In this anal­
ysis DMPM vesicles containing small amounts of 3H- and R e ­
























Substrate specificity of conodipine-M 
Radiolabeled substrates are present in  DMPM vesicles. See “Exper­
im ental Procedures” for additional details.
Radiolabeled substrates (kcJK mfl(kaLtIK Jli
[3H]DPPC vs. [14C]SAPC 1.04
[3H]DPPC vs. [14C]SAPI 0.71
[3H]DPPE vs. [14C]SAPC 0.20
[3H]DPPA vs. [14C]SAPC 0.13
[3H]SAPS vs. [14C]SAPC 0.33
1 2 3 4 5 6 7 8 9  
Fraction num ber
Fig. 5. Conodipine-M  (23 |tg ) w as ru n  on a  HPLC colum n using  
cond itions described  in  p a n e l C o f Fig. 1. Fractions were collected 
every 30 s as indicated. Absorbance was monitored a t 220 nM (solid 
line). One percent of each fraction was tested  for PLA2 activity using the 
DMPM/polymyxin B assay described under “Experim ental Procedures.” 
Activity (nmol of NaOH titra n t used per min in  the pH-stat) is norm al­
ized such th a t the maximum activity (10.6 nmol/min) is plotted a t the 
same ordinate value as the UV absorbance. Note th a t the PLA2 activity 
profile (open circles) also corresponds to the protein absorbance profile.
[Ca] uM
Fig. 6. C alcium  dependence of th e  conodipine-M -catalyzed 
hydrolysis o f [3H]DPPC in  DMPM vesicles. Conditions are given 
under “Experim ental Procedures.”
each other for hydrolysis by the enzyme. Substrate specificity 
studies using vesicles containing single species of phospholip­
ids are less meaningful because the observed preferences will 
be due, in part, to differential amounts of enzyme bound to the 
different vesicles (60). The competitive double radiolabel anal­
ysis gives the intrinsic substrate specificities of the enzyme 
which are defined by the relative k cat/Km values for the various 
substrates. Thus, if the vesicle contains an equal concentration 
of two competing substrates, the ratio of velocities for hydrol­
ysis of the different phospholipids is equal to the ratio of 
k caJK m values for the same phospholipids. Relative k cslt/Km 
values for the action of conodipine-M on vesicles are given in 
Table III. The general feature is that conodipine-M has broad 
specificity toward different phospholipids. The enzyme does not
discriminate between sn -2 palmitoyl versus sn -2 arachidonyl 
chains, and only modest discriminations (up to 8-fold) are seen 
for phospholipids with various polar head groups. When cono- 
dipine-M is added to DMPM vesicles containing [3H]DPG and 
[14C]SAPC, only the phospholipid is hydrolyzed. Thus, conodi­
pine-M has no diacylglycerol lipase activity.
Additional phospholipids were tested as possible substrates 
of conodipine-M. The reactions were carried out in 4 ml of 0.6 
mM CaCl2, 1 mM NaCl, pH 8.0, containing 0.6 mg of phospho­
lipid, 20 /xg of polymyxin B, and 0.07 /xg of conodipine-M at 
21 °C in the pH-stat. The enzyme readily hydrolyzes vesicles of 
l,2-dioleoyl-s«-glycero-3-phosphomethanol, but vesicles of the 
D-stereoisomer were not detectably hydrolyzed. Thus, conodi­
pine-M, like other PLA2s, is stereospecific for phospholipids 
with the natural stereochemistry at the glycerol backbone. 
Under the same conditions the lysophospholipid 1-myristoyl- 
sra-glycero-3-phosphocholine is not a substrate. Conodipine-M 
hydrolyzes vesicles of the zwitterionic phospholipid 1,2-dimyr- 
istoyl-sn-glycero-3-phosphocholine, although the turnover num­
ber of 10 s "1 is considerably less than 200 s 1 measured with 
DMPM vesicles. Since fully vesicle-bound conodipine-M does 
not significantly discriminate between phospholipids with dif­
ferent polar head groups, the low turnover rate on zwitterionic 
vesicles may be due to poor binding of enzyme to the interface 
as is the case for many 14-kDa PLA2s (45, 56, 61), but this was 
not investigated further.
Conodipine-M has no triacylglycerol lipase activity. Adding 
0.15 /xg of conodipine-M to 7 mM tributyrin in 4 ml of 0.6 mM 
CaCl2, 1 mM NaCl, 20 /xg of polymyxin B, pH 8.0, at 21 °C in the 
pH-stat did not result in detectable hydrolysis, whereas adding 
0.25 /xg of pancreatic lipase gave rise to an immediate reaction. 
Conodipine-M also failed to hydrolyze 0.3 mM triolein in a 
reaction mixture containing 20 mM deoxycholate, 0.6 mM 
CaCl2, 1 mM NaCl, pH 8.0, a t 21 °C in the pH-stat. Under such 
conditions, hydrolysis was detected after adding pancreatic 
lipase.
Conodipine-M did not detectably hydrolyze [3H]DPG present 
in DMPM vesicles, although [14C]PAPC present in the same 
vesicles was hydrolyzed. Thus, conodipine-M has no diglyceride 
lipase activity.
Inh ib itors o f  C onodipine-M —As shown in Fig. 7 conodi- 
pine-M is inhibited by two compounds, linoleoyl amide and 
MG14, which have been previously shown to inhibit 14-kDa 
PLA2s (47-49). Inhibition studies were carried out by adding 
inhibitors to DMPM vesicles and measuring the initial velocity 
for the hydrolytic reaction. Since the enzyme is tightly bound to 
DMPM vesicles, the inhibition must be due to a direct enzyme/ 
inhibitor interaction rather than to a decrease in the fraction of 
enzyme bound to the membrane (62, 63). The mol fractions of 
linoleoyl amide and MG14 in DMPM vesicles which cause a 
50% decrease in the initial velocity are 0.001 and 0.003, respec­
tively, and thus these compounds are potent conodipine-M 
inhibitors.
DISCUSSION
The results demonstrate that conodipine-M is a novel PLA2; 



























Sequence comparison o f catalytic residues 
Sequences containing catalytic residues in group I—III PLAjS are 
compared with potentially similar sequences in conodipine-M. Proposed 
group numbers are shown in parentheses. BTX, bungarotoxin.
Enzyme Sequence Residue no.
Porcine pancreas (I) R C C E T H D N C y 43-52
0-BTX (I) R c c Y V H D N C Y 39-48
B. gabonica (II) R c c F V H D C c Y 37—46
Bee venom (III) A c c R T H D M c P 29-38
Consensus X c c 
—1
X X H D X c X
Conodipine-M (V) A 4 D R H D T c Y 31—40
Enzyme Sequence Residue no.
Mole Fraction Inhibitor
F ig .  7. In h ib ition  o f conodipine-M -catalyzed hydrolysis of 
DMPM vesicles by linoleoyl am ide (filled  circles) an d  MG14 
(open circles) p re sen t in  DMPM vesicles a t  th e  in d ica ted  mol 
frac tion . O ther conditions are given under “Experim ental Procedures.”
from cone snail venom. We have named this enzyme conodip- 
ine-M and anticipate that this is only the first of a family of 
PLA2 enzymes present in these venoms. In another Conus 
venom, Conus caracteristicus, a related enzyme has been par­
tially characterized.2 Thus, we propose tha t other PLA2 en­
zymes belonging to this family should also be referred to as 
conodipines (the major enzyme from C. caracteristicus would be 
referred to as conodipine-C; sequence variants of conodipine-M 
from C. m agus  would be referred to as conodipine-M 1, conodi- 
pine-M2, etc.).
Conodipine-M was identified by an unusual route; the assay 
actually used to purify this PLA2 activity was not enzymatic 
activity but rather the inhibition of binding of a dihydropyri­
dine drug to L-type calcium channels in ra t brain membranes. 
We have demonstrated tha t purified conodipine-M potently 
inhibits [3H]isradipine binding under standard assay condi­
tions. There are two general possibilities, (i) The inhibition may 
be relatively nonspecific, i.e. PLA2 may be solubilizing the 
L-type calcium channel; if binding sites can no longer be fil­
tered, this would appear as inhibition, (ii) An alternative ex­
planation is that the PLA2 produces a metabolite (perhaps 
derived from arachidonic acid) which inhibits binding of isra- 
dipine to L-type calcium channels. These possibilities are pres­
ently being investigated. It is notable, however, that a 10-fold 
greater concentration of conodipine-M than is required to in­
hibit completely the binding of [3H]isradipine to L-type calcium 
channels exhibits no detectable effect on the binding of 125I- 
labeled oi-conotoxin GVTA to N-type calcium channels, even 
though both assays employ filtration of membranes (55).
Conodipine-M has two distinct polypeptide chains that are 
apparently linked to each other through one or more disulfide 
bonds; upon reduction of disulfides, conodipine-M is dissociated 
in two unequally sized subunits. A similar situation is found 
with several snake venom PLAgS that have multiple subunits. 
In some cases, at least one of the subunits appears to be used 
for targeting the PLAg to a particular membrane component 
(e.g. the /3-chain of bungarotoxin interacts with potassium 
channels) (64). It is possible that one of the two subunits of 
conodipine-M is responsible for the catalytic activity, with the 
other subunit involved in targeting the enzyme to specific sites. 
The physiological function of PLA2 within C. m agus venom 
remains a m atter for conjecture, but it is of interest that this 
activity is apparently present in other Conus venoms, which
2 S. R. N aisbitt and J. M. McIntosh, unpublished results.
Porcine pancreas (I) C N C D R N A A I C F 96-106
/3-BTX (I) c D C D R T A A L C F 84-94
B. gabonica (II) c E c D R V A A I c F 78-88
Bee venom (III) c D c D D K F Y D c L 61-71
Consensus c_ X c D X X X X X_c_ X
Conodipine-M (V) D D _c^ D D A F F R D M 51-61
specialize on different prey.
More than 50 PLA2s from venoms have been sequenced to 
date, and three sequence groups are apparent (32). Group I is 
composed of PLA2s from elapid and Old World snakes. Mem­
bers of group II include crotalids and viperids of the New 
World. Group I and group II sequences are highly homologous 
to each other. The major differences lie in the positioning of the 
one of the seven disulfides, and group II enzymes have a short 
COOH-terminal extension. Group III PLA2s, which include the 
enzymes from bee and lizard venoms, are only about 20% 
homologous to group I and II enzyme (41). A novel PLA2, group
IV, has recently been purified from the cytosol of a number of 
proinflammatory mammalian cells. It has a molecular weight 
of 85,000, and its amino acid sequence shows no homology to 
group I—III enzymes (21, 65, 66).
The amino acid sequence of conodipine-M does not reveal any 
obvious homology with group I-IV PLA2s. However, some sim­
ilarity may exist in sequences including and near amino acid 
residues that are known to function in the active site. In group 
I—III PLA2s a histidine residue, which functions as a general 
base in assisting the attack of a water molecule on the sub­
strate ester, is followed by an aspartate that is one of the 
ligands for the active-site calcium cofactor. This pair of resi­
dues is flanked by 3 cysteines (Tables II and IV). The a-chain of 
conodipine-M has a histidine-aspartate pair flanked by 2 cys­
teines instead of three, but it is not known whether these 
residues function in a way analogous to those in group I—III 
PLA2s. Group I—III PLA2s have an aspartate that is hydrogen- 
bonded to the catalytic histidine residue and is flanked by 3 
cysteines (Tables II and IV). The a-chain of conodipine-M has 
an aspartate residue with only 1 nearby cysteine (Tables II and 
IV). The sequence Tyr/Trp-Cys-Gly-Xaa-Gly is found in all 
group I—III PLA2s. The carbonyl oxygens of the 2 glycines of 
this sequence are ligands to the calcium cofactor. Conodipine-M 
lacks such a sequence.
Like the other enzymes, conodipine-M requires calcium for 
its PLA2 activity, although the concentration of calcium that 
gives 50% of maximal activity (about 20 fxM) is considerably 
lower than typical values for group I—III enzymes (a few hun­
dred i-lm). It is thus significant that conodipine-M lacks the 
otherwise conserved calcium binding residues. All sequence 
factors considered, conodipine-M clearly represents a very 
structurally diverse enzyme, and we therefore propose to clas­























Given the low homology to other PLA2s, it is remarkable that 
conodipine-M displays many other features of venom PLA2s as 
well. The phospholipid analog MG 14 is a transition state ana­
log inhibitor of group I—III enzymes, and the fact that it is also 
a potent inhibitor of conodipine-M suggests that the catalytic 
mechanism of the Conus enzyme may be similar to the other 
venom enzymes. Also, the pH-rate profile for conodipine-M is 
similar to those for group I—III enzymes. For these latter en­
zymes the pH dependence reflects, in part, that the active-site 
histidine is in the nonprotonated form to function as a general 
base in the catalytic reaction (67). Conodipine-M, like other 
venom PLA2s, does not significantly discriminate between 
phospholipids with different polar head groups or unsaturated 
versus saturated acyl chains. Further structural studies of 
conodipine-M will be required to understand fully its catalytic 
mechanism and to compare it with other known PLA2s. It is not 
known which conodipine-M subunit contains the phospholipase 
activity, but as discussed above, the a-chain may have similar 
catalytic sequence motifs. The amino acids that we have pos­
tulated as key catalytic residues need to be confirmed experi­
mentally. Our speculation clearly predicts, however, that cat­
alytic activity will be carried out primarily by the a-chain.
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